Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.

ABSTRACT: Endometrial cancer incidence and mortality are rising among all ethnic groups. Carboplatin plus paclitaxel is the established frontline treatment for advanced/recurrent disease; however, subsequent treatment with traditional cytotoxic chemotherapy is challenging. The molecular characterization of endometrial cancer has provided important insights into the biological drivers of carcinogenesis, which has allowed for the development of newer precision immunotherapies and targeted therapies, including pembrolizumab, dostarlimab, and lenvatinib. Until recently, platinum rechallenge was often considered at the time of recurrence, given the lack of other available therapeutic options; however, "platinum sensitivity" in endometrial cancer is subjective and largely based on expert opinion and/or pr

SUBMITTER: Rubinstein M 

PROVIDER: S-EPMC10373231 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature